New COVID-19 Vaccine Data;  Protection Gained by 3rd and 4th Doses

Translate to Spanish or other 102 languages!

A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant. Image for illustration purposes
A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant. Image for illustration purposes

Mega Doctor News

- Advertisement -

A third and fourth COVID-19 vaccine dose offered substantial protection among adults with healthy immune systems who were eligible to receive them during Omicron variant evolution in early 2022, according to a new MMWR published today. The findings of this study, in conjunction with recently published data showing people infected with BA.2 may also have antibodies that can protect against illness with BA.5, suggest that currently available vaccines may provide protection against serious illness caused by the currently circulating BA.5 variant.

To evaluate effectiveness of 2, 3, and 4 doses of mRNA COVID-19 vaccines (Pfizer-BioNTech or Moderna) among adults with healthy immune systems, experts examined VISION Network data on more than 214,000 emergency department/urgent care visits and more than 58,000 hospitalizations with a COVID-19–like illness diagnosis in 10 U.S. states from mid-December 2021 through mid-June 2022. Study findings show:

  • When BA.1 was the predominant variant, vaccine effectiveness (VE) was 61% for two doses against COVID-19-associated hospitalizations; VE increased to between 85%–92% after receipt of a third/booster dose.
  • When BA.2/BA.2.12.1 became predominant, vaccine effectiveness with two doses was 24% against COVID-19-associated hospitalizations and increased to 52%–69% after a third/booster dose.
  • Patterns were similar for emergency department and urgent care encounters, with lower VE during BA.2/BA.2.12.1 predominance and higher VE with 3 or 4 doses compared to VE with 2 doses.
  • Among adults ages 50 years and older during BA.2/BA.2.12.1, vaccine effectiveness against COVID-19–associated hospitalization was 55% more than 4 months after a booster/third dose and increased to 80% more than a week after the fourth dose

COVID-19 vaccines remain our single most important tool to protect people against serious illness, hospitalization, and death. Getting vaccinated now will not prevent you from getting an authorized variant-specific vaccine in the fall or winter when they are recommended for you.  Given recent increases in deaths and hospitalizations associated with the BA.5 variant, everyone should stay up to date with recommended COVID-19 vaccinations, including additional booster doses for those who are moderately to severely immunocompromised and adults over 50.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health to Host Free Adult Epilepsy Seminar, Aug. 15th

 DHR Health, together with the Epilepsy Foundation Central and South Texas, will host a free community health education seminar that will focus on epilepsy and supporting adults living with the condition

Lab-Grown Mini Organs Show Promise in Predicting Breast Cancer Treatment Outcomes

Researchers at UC San Francisco have developed a new method to predict how different types of breast cancer will respond to treatment, using patient data from the I-SPY2 breast cancer trial and rapid testing on lab-grown mini tumors. 

STHS Hosting Community Blood Drive Amid National Blood Shortage, August 21st 

The United States is facing a severe blood shortage, prompting the American Red Cross to issue only the second national blood crisis declaration in its history.

DHR Health Recertified for Advanced Hip & Knee Replacements

DHR Health has once again earned The Joint Commission's Advanced Certification in Total Hip and Total Knee Replacement, reaffirming its commitment to providing high-quality, patient-centered orthopedic care to the Rio Grande Valley.
- Advertisement -